Companies: 10,795·Total market cap: $144.5T
Enzolytics Inc.

Enzolytics Inc.

ENZCOTCHealthcare● Active
$0.00
+$0.00(+10.00%)
Market Cap$4335804
P/E Ratio
52W High$0.0012
52W Low$0.0002
Overview

Enzolytics Inc.(ENZC)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · ENZC · 截至 Jun 9, 2026

关键指标

EPS (TTM)$-0.00enzc eps ttm · enzc earnings per shareEarnings history
PE Ratio (TTM)enzc pe ratio ttm · enzc price to earningsPE Ratio deep dive
Revenue (TTM)0.00enzc revenue ttm · enzc annual revenueFull revenue history
Dividend Yield不分红does enzc pay dividends · enzc dividend yieldDividend history
Shares Outstanding3.44Benzc shares outstanding · enzc floatShares outstanding history
Next EarningsTBAenzc earnings date · enzc next earningsEarnings history

财务快照

完整财报
FY 2025Revenue$0.00
202320242025
enzolytics inc. revenue · enzc revenue 2025
FY 2025Net Income-$92239.00▲ +76.59% YoY
202320242025
enzolytics inc. net income · enzc profit 2025
FY 2025EPS$0.00▲ +100.00% YoY
202320242025
enzc eps · enzolytics inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$404091.00EPS: $-0.00View income statement →

股票表现

完整历史
1D+10.00%
1W+10.00%
1M+83.33%
3M+120.00%
YTD+266.67%
1Y+57.14%
5Y-99.58%

关于 Enzolytics Inc.

CEOSteven Sharabura
IPO DateApr 8, 2009
Employees1
CountryUS

Enzolytics Inc. a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing…

what is enzolytics inc. · enzc stock overview · enzolytics inc. company profile · who is enzolytics inc. ceo · enzc OTC · enzolytics inc. headquarters · enzolytics inc. business segments

关于股票概览与关键数据

Enzolytics Inc.(ENZC)是 Biotechnology 行业的 Healthcare 类公司,于 Apr 8, 2009 在 OTC 上市。截至最近交易日,ENZC 股价为 $0.00,市值约为 $4.3M。过去12个月累计回报 +57.14%,年初至今回报 +266.67%。

2025 财年 Enzolytics Inc. 营收 —。完整财务数据(营收历史、盈利、资产负债表)请使用上方标签页。

常见问题

截至最近一个交易日,Enzolytics Inc.(ENZC)股价为 $0.00,在 OTC 上市,52周区间为 $0.00 – $0.00。

ENZC 最新股价ENZC quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 9, 2026本内容不构成投资建议